Tradewinds Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Tradewinds Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-191	Closed	-$12K	–	694
2019 Q4	$12K	Hold	191	–	–	﹤0.01%	384
2019 Q3	$12K	Hold	191	–	–	﹤0.01%	352
2019 Q2	$14K	Hold	191	–	–	0.01%	318
2019 Q1	$15K	Hold	191	–	–	0.01%	325
2018 Q4	$16K	Hold	191	–	–	0.01%	309
2018 Q3	$33K	Hold	191	–	–	0.01%	254
2018 Q2	$25K	Hold	191	–	–	0.01%	285
2018 Q1	$20K	Hold	191	–	–	0.01%	300
2017 Q4	$16K	Hold	191	–	–	0.01%	357
2017 Q3	$16K	Hold	191	–	–	0.01%	337
2017 Q2	$14K	Hold	191	–	–	0.01%	348
2017 Q1	$13K	Buy	+191	New	+$12.6K	0.01%	361

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Tradewinds Capital Management's LGND Position: Q1 2020 in Review

Tradewinds Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 191 shares — an estimated $12K sold.

Tradewinds Capital Management first reported a position in LGND in Q1 2017 and held it in 12 quarters. The position peaked at $33K in Q3 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

Tradewinds Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Tradewinds Capital Management sold 191 Ligand Pharmaceuticals shares in Q1 2020, an estimated $12K.
Tradewinds Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 12 quarters.
Tradewinds Capital Management's Ligand Pharmaceuticals position peaked at $33K in Q3 2018.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Tradewinds Capital Management's 13F filing for Q1 2020, filed 11 May 2020.